NEUPOGEN Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NEUPOGEN
High Confidence Patents: | 5 |
Applicants: | 1 |
BLAs: | 1 |
Drug Prices: | Drug price information for NEUPOGEN |
Recent Clinical Trials: | See clinical trials for NEUPOGEN |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NEUPOGEN |
Recent Clinical Trials for NEUPOGEN
Identify potential brand extensions & biosimilar entrants
Sponsor | Phase |
---|---|
Medical College of Wisconsin | Phase 1 |
Newlife Fertility Centre | Phase 4 |
St. Jude Children's Research Hospital | Phase 1/Phase 2 |
Recent Litigation for NEUPOGEN
Identify key patents and potential future biosimilar entrants
District Court Litigation
Case Name | Date |
---|---|
Pandora Marketing LLC | 2024-01-31 |
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD. | 2023-01-19 |
JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN INC. | 2021-07-28 |
PTAB Litigation
Petitioner | Date |
---|---|
2016-09-15 | |
2012-09-25 |
Pharmacology for NEUPOGEN
Physiological Effect | Increased Myeloid Cell Production |
Established Pharmacologic Class | Leukocyte Growth Factor |
Chemical Structure | Granulocyte Colony-Stimulating Factor |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NEUPOGEN Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NEUPOGEN Derived from Company Disclosures
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 4,810,643 | 2006-03-07 | Company disclosures |
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 4,999,291 | Company disclosures | |
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 5,528,823 | Company disclosures | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NEUPOGEN Derived from Patent Text Search
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
---|---|---|---|---|---|---|---|
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 10,016,338 | 2033-03-11 | Patent claims search |
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 10,039,808 | 2039-02-26 | Patent claims search |
Amgen Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 10,053,498 | 2034-11-21 | Patent claims search |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for NEUPOGEN
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 1018552 | ⤷ Try for Free |
Japan | H09224670 | ⤷ Try for Free |
Japan | H06181791 | ⤷ Try for Free |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NEUPOGEN
Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|
SPC/GB14/009 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: LIPEGFILGRASTIM; REGISTERED: UK EU/1/13/856/001 20130729 |
C 2014 004 | Romania | ⤷ Try for Free | PRODUCT NAME: LIPEGFILGRASTIM; NATIONAL AUTHORISATION NUMBER: EU/1/13/856; DATE OF NATIONAL AUTHORISATION: 20130725; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/856; DATE OF FIRST AUTHORISATION IN EEA: 20130725 |
2014C/003 | Belgium | ⤷ Try for Free | PRODUCT NAME: LIPEGFILGRASTIM; AUTHORISATION NUMBER AND DATE: EU/1/13/856 20130729 |
>Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for the Biologic Drug: Neupogen
More… ↓